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Regression of left ventricular hypertrophy in hypertensive dialyzed
uremic patients on long-term antihypertensive therapy. There have been
no studies of the possibility of reversing the left ventricular hypertrophy
(LVH) of chronically hemodialyzed hypertensive uremics (HDH) with
long-term antihypertensive therapy. We have measured left ventricular
sizes of eight (6 male, 2 female, aged 29 to 61 years) HDH with M-mode
echocardiography, before and 12, 18 and 24 months after the start of a
combined antihypertensive therapy which included ACE-inhibitors,
beta-blockers and calcium-antagonists. Pre-treatment values for mean
blood pressure (MBP), 116.6 2.9 mm Hg, end diastolic diameter
(EDD), 62.6 6.6 mm, interventricular septum (IVS), 14.2 3.0 mm,
and left ventricular mass index (LVMi) , 239 61 g/m2, were all
significantly higher than those for nine sex- and age-matched hemodi-
alyzed normotensive subjects (HDN) with comparable hemoglobin
(Hb) levels. During the antihypertensive treatmert, both the systolic
and diastolic BP decreased steadily (P = 0.0001; P = 0.0003; ANOVA)
and significantly by the third month (P < 0.05; P < 0.01), reaching
levels comparable o those of the HDN group after 12 months. At this
time the LVMi (204 67) and the IVS (13.1 2.7), although both
significantly lower than baseline, were still higher than in the HDN
group, while the EDD was similar. After 24 months, however, both the
IVS (12.3 3.1) and the LVMi (161 65 ) were no longer different from
those of the HDN group. Thus, this study is the first to demonstrate that
prolonged antihypertensive therapy with strict blood pressure control is
able to considerably reduce the LVH of chronically hemodialyzed
uremic patients, indicating the key role of arterial hypertension in
inducing pathological growth of the LVM in these subjects.
It is known that left ventricular hypertrophy (LVH) of
essential hypertensives can be reversed by effective antihyper-
tensive therapy [1, 21. Long standing arterial hypertension is
also suspected to be a leading cause of LVH in patients with
end-stage renal disease [3, 4]. On the other hand, previous
studies of such patients did not demonstrate a clear etiopatho-
genetic role of arterial hypertension, since LVH progressed
with time in spite of adequate blood pressure (BP) control [5, 6].
Furthermore, in a more recent study, oral nitrendipine given for
24 weeks had no measurable effect on the heart size of these
subjects, although it significantly decreased the pre-dialysis BP
[7]. To date no reports of the effects of strict BP control with
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prolonged antihypertensive therapy on LVH of chronic hyper-
tensive uremic patients are available.
We have studied prospectively a selected group of dialyzed
uremic patients, before and during an antihypertensive regimen
lasting two years, by echocardiography.
The data presented here indicate that prolonged antihyper-
tensive therapy effectively lowered the BP of these subjects and
considerably decreased the left ventricular mass (LVM).
Methods
Subjects
The subjects in this study were recruited from a cohort of
nearly 130 patients currently treated at our hemodialysis unit.
Patients who had been dialyzed for less than six months were
excluded. Other exclusion criteria were: obesity; diabetes;
peripheral, cerebral and coronary vascular diseases; past or
recent evidence of myocardial infarction; angina pectoris; re-
current congestive heart failure; significant valvular regurgita-
tions; neoplastic diseases, and anemia with hemoglobin (Hb)
lower than 8.5 g/dl.
Routine echocardiograms made during the last few months
were reviewed and only subjects with echotracings of optimal
quality were selected initially. Patients who agreed to partici-
pate in the study underwent 24-hour continuous interdialysis
ambulatory BP monitoring (CABPM), which was repeated after
a period of one month on placebo treatment. Five patients had
already been on antihypertensive therapy. For these patients,
the antihypertensive medications were gradually tapered off
over a week before they started to take the placebo. Patients
were arbitrarily defined as "hypertensive" when their systolic
and diastolic BP were >150/90 mm Hg in at least 70% of the
total readings from both sets of CABPM, and were defined
"normotensive" if their BP were <150/90 mm Hg in at least
70% of the total readings.
Patients who were finally selected included eight (6 males, 2
females, aged 29 to 61 years) hemodialyzed hypertensive
(HDH) and nine sex- and age-matched hemodialyzed normo-
tensive (HDN) subjects.
All of them were dialyzed with bicarbonate three times a
week, with the duration of treatment (3.5 to 4.5 hr) and dialyzer
surface (1.3 to 1.8 m2), prescribed individually according to the
urea-kinetic model criteria [8]. The ideal "dry" body weight
was assessed on a clinical basis [9], and for dubious cases, by
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Table 1. Values for eight hypertensive hemodialyzed uremic patients (1-LDH) and for nine sex- and age-matched hemodialyzed normotensive
controls (HDN)
Basal 12 Months 24 Months
HDH HDNHDH HDN HDH HDN
Body wt kg 63.7 11 64.4 12.7 62.6 11 64.2 14 64.6 12.1 64.1 12.4
Bodywt% 3.9 0.7 4.1 0.6 4.2 0.9 4.1 0.9 4.4 1.1 4.2 0.9
Kt/V 1.20 0.09 1.18 0.16 1.22 0.1 1,20 0.1 1.18 0.07 1.21 0.09
Hb gIdi 10.1 1.3 10.3 1.4 10.6 1.2 10.2 0.8 11.2 0.9 10.7 1.1
IPTH pg/mI 242 253 253 296 279 259 323 322 250 300 336 433
ALPU/liter 335 317 414 390 386 536 526 605 335 363 506 590
Al p,g/liter 15.9 14.2 11.8 8.7 19.9 13.8 16.4 8.0 16.1 7.3 14.2 4.8
Abbrevations are: Body wt, percent intradialytic increase in body weight; Hb, concentrations of hemoglobin; iPTH, plasma parathyroid
hormone; ALP, alkaline phosphatase; and Al, serum aluminum.
Data are mean SD,
a Significant difference (P <0.05) with respect to the first measurement
caval echography [10]. The subjects ate a diet with protein
content from 1.1 to 1.2 g/day and unrestricted salt intake. They
were taking calcium carbonate or acetate tablets and vitamin D
supplements and were given recombinant human erythropoietin
(rHuEPO) i.v. or subcutaneously at a dosage adequate for
maintaining their Hb levels at about 10 gldl. There were serial
determinations of Hb, plasma aluminum, alkaline phosphatase
and intact circulating parathyroid hormone (iPTH; normal
values in our laboratory from 10 to 65 pg/mI) was determined by
radioimmunoassay (RIA Allegro, Nichols Institute, Texas,
USA).
BP was monitored throughout the entire study by measuring
supine BP with an automated arm-cuff device. The measure-
ments lasted 15 minutes and were taken monthly during a
midweek interdialysis day, just before the next hemodialysis
and within 20 minutes after the hemodialysis ended. These
three sets of measurements were averaged and the resulting BP
level was recorded. For day-to-day purposes, the BP was also
measured before and after each dialysis session by a mercury
sphygmomanometer. At the end of the study, all subjects of
both groups were again monitored by CABPM.
The goal of antihypertensive therapy was to obtain supine
DBP within 75 to 85 mm Hg and SBP below 140 mm Hg. The
HDH patients were started on oral treatment with 25 mg
atenolol and 5 mg lisinopril at the end of each dialysis session
and with a daily dose of 20 mg of slow-release nifedipine tablets.
In an attempt to ensure strict compliance with the therapy, the
post-dialysis therapy was given under the surveillance of a
nurse and home therapy was checked by a pill count.
The therapy was titrated every month from the average BP
measured with the automated arm-cuff device. If the goal had
not been achieved, the dosage of each drug was increased, up to
maximal dose of 50 mg atenolol, 10 mg lisinopril every 48 hours
and 60 mg nifedipine a day.
All echocardiograms were taken on a midweek interdialysis
day. Echocardiograms of HDH patients were made within one
week before the start of the antihypertensive regimen and 12, 18
and 24 months thereafter. For the HDN group, records were
not taken at the 18th month. The echotracings were collected by
a two-dimensional guided M-mode echocardiograph, according
to widely accepted criteria [Ii]. All echocardiograms were
taken by the same cardiologist (S.M.), coded by a third party
(G.C.) and read at random by an experienced observer (R.D.)
who was blind to the subject's identity and to the design of the
study. The echocardiographic measurements included the end
diastolic diameter of the left ventricular chamber (EDD, normal
range in our laboratory 41 to 52 mm), the interventricular
septum thickness (IVS, n F: 6 to 11 mm) and the thickness of the
left ventricular posterior wall (PW, n r: 6 to 10.5 mm). The
intraobserver variability for these measurements in repeated
studies averaged 6%. The LVM was calculated from these
measurements according to the modified Penn-cube formula
[121 and indexed per square meter of body surface area (bsa).
The cut-off level for defining LVH was  120 g/m2, which is the
highest value we found in our laboratory for a group of 32
normal subjects (20 males, 12 females, aged 20 to 56 years, body
wt 45 to 90 kg and bsa 1.34 to 2.1 m2).
Results are presented as means SD. Within-patient com-
parisons were made by analysis of variance for repeated mea-
sures (ANOVA). When the F test was significant, then the
Student (-test was used for comparison of two groups. Differ-
ences between patients and control subjects were evaluated by
the Student (-test for unpaired data.
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Fig. 1. Systolic and diastolic blood pressures (mean so) for nine
hemodialyzed normotensive uremic patients (U) and for eight hemodi-
alyzed hypertensive subjects (•) on antihypertensive therapy with beta
blockers, Ca antagonists and ACE inhibitors for 24 months. Asterisks
indicate significance (***P < 0.005; ** < 0.01; "p < 0.05) with respect
to the previous time, or between groups (within parentheses).

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plasma aluminum concentrations of the two groups were very
similar and did not change significantly during the study.
Circulating Hb concentrations were also similar and increased
significantly, although to a small extent, only in the HDH
group.
Diastolic and systolic BP of the HDH patients decreased
significantly (F = 4.5; P = 0.0003; F = 6.3; P = 0.0001;
ANOVA) on antihypertensive therapy (Fig. 1). Two main
drops were observed, the first between the first and the third
months and the second between the 12th and the 15th months.
After this time no further significant changes were seen. By
definition, both the SBP and the DBP were significantly higher
in the HDH than in HDN group. After the 12th month,
however, the BP of both groups were no longer distinguishable.
(Fig. 1).
At the end of the study period, when the CABPM collected
for both groups were pooled and compared with the automated
arm-cuff measurements, the differences were 2 2 mm Hg for
SBPand —1 2forDBP.
Table 2 lists data for echocardiographic records taken every
twelve months for both groups of subjects.
Resting values for EDD, IVS and PW were all significantly
higher in HDH than in HDN patients. On antihypertensive
treatment, both EDD and the IVS decreased significantly to
values that, after 24 months, were no longer significantly
different from those of normotensive patients. The IVS/PW
ratio for the HDH patients was higher than for the HDN group
—P< 0.05—
and decreased considerably thereafter, although still remaining
(NS) higher than in the HDN group.
The baseline LVMi for the hypertensive patients was 239
12 18 24 61 gIm2, which was significantly greater (P < 0.005) than that of
the normotensive patients (Fig. 2). During antihypertensive
therapy there were significant decreases in the LVMi (F = 40;
P = 0.001; ANOVA). Analysis of the individual basal data
revealed that all patients from the HDH group had LVMi above
the cut-off limit already established from normal subjects. It
was also observed that three of eight hypertensive subjects had
LVMi overlapping with those of the HDN group. After twelve
months of treatment, the LVMi of the HDH group had de-
creased to 204 67 g/m2, which was significantly less than the
baseline value (P < 0.01), but still greater than that for the HDN
(P < 0.02). When the HDH were studied six months later,
LVMI was found to have decreased further to a value of 173
63 g/m2, which is lower (P < 0.01) than that at the 12th month.
When all the patients were restudied again at 24 months, the
LVMI of the HDH patients had decreased to 161 65 g, which
was significantly lower (P < 0.05) than that at the preceeding
Table 2. Data for echocardiographically measured left ventricular end-diastolic diameter (EDD), interventricular septum (IVS) and left
ventricular posterior wall (PW) for eight hemodialyzed hypertensive subjects (HDH) undergoing antihypertensive therapy with beta blockers, Ca
antagonists and ACE inhibitors for 24 months compared to those of nine normotensive sex- and age-matched hemodialyzed uremic subjects (HDN)
Basal 12 Months 24 Months
—
HDH HDNHDH HDN HDH HDN
EDD mm 62.6 6.6e 54.9 4.7 55.7 7.2 52.6 3,5C 49.6 8.2a 51.9 33C
IVS mm 14.2 30d 9.9 1.4 13.1 2.7c1 9.2 1.2 12.3 3.1c 10.0 1.4
PW mm 10.4 l.4 8.9 0.9 11.4 l.9 9.4 0.8c 11.0 2.3 10.1 1,1b
IYS/PW 1.36 O.2 1.12 0.2 1.15 0.2c 0.99 0.1C 1.11 0.1
aP<0.01, b P < 0.02, P < 0.05 indicate differences with respect to the basal values
d p < 0.005, e p < 0.02, P < 0.05 indicate differences between groups
>
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Fig, 2. Indices of left ventricular mass (LVMi)for eight (2 females, D;
6 males, A) hemodialyzed hypertensive uremic patients before and after
starting antihypertensive treatment with beta blockers, Ca antagonists
andACE inhibitors for 24 months. Horizontal bars depict mean values.
Also indicated are means SD and ranges (dashed columns) for nine
sex- and age-matched normotensive dialyzed subjects. The shaded area
on the vertical axis is the range for LVMi in 32 normal subjects. The P
values for the between-groups differences (Student t-test for unpaired
data, within parentheses) or within-groups (Student 1-test for paired
data) are shown.
Results
Table 1 shows some pertinent clinical data for both groups.
The average basal values for body wt, interdialysis body wt
gain (A% body wt), kT/V, PTH, alkaline phosphatase and
—P< 0.001—
(P<0.005) (P<0.005)
0
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time and no longer significantly higher than that of the HDN
group. At this time, three of eight hypertensive patients now
had values for LVMi within, or even below, the range of LVMi
for HDN subjects (Fig. 2).
Discussion
Severe LVH frequently develops in patients with end-stage
renal disease [13] and is often associated with a poor cardio-
vascular prognosis [3].
Prospective echocardiographic studies have demonstrated
the progressive nature of the disease, with both the thickness
[5] and the internal dimensions [5, 6, 14] of the left ventricle
tending to increase with time. Therefore, slowing the rate of this
progression or reversing an already established LVH might be
of major clinical importance for these patients with very poor
cardiovascular prognosis. The pathogenesis of LVH in chronic
uremic patients is a very complex problem involving many
etiopathogenetic factors [14], with chronic anemia [4, 15, 161
and uncontrolled arterial hypertension [3, 4] possibly the main
ones. However, while partial correction of the anemia by
recombinant human erythropoietin (rHuEPO) has been shown
to be effective in reversing the LVH in these subjects [16], the
true effectiveness of antihypertensive therapy remained to be
established [5, 17]. Since prospective studies specifically ad-
dressing this issue had never been done, we decided to do an
echocardiographic study of the LV of a group of hypertensive
dialyzed uremics, before and during long-term combined
antihypertensive treatment. Since the purpose of this study
was to elucidate the impact of the arterial hypertension on the
LVM and the effects of the antihypertensive treatment on the
natural course of LVH, patients were selected from a large
population of hemodialysis patients to strictly avoid factors
known to affect the LVM that might interfere with interpreta-
tion of the data.
In this work we set our target blood pressure arbitrarily at
150/90 and any BP above that level was defined as poorly
controlled hypertension. Proper assessment of BP requires
prolonged BP monitoring to ascertain the existence of an
underlying arterial hypertension [18]. In the present study a
whole-day ambulatory BP recording was made with a portable
monitor and both the prevalence and the magnitude of the BP
load were assessed on the basis of these repeated measures.
After the start of the antihypertensive therapy, we monitored
the BP by averaging three sets of measurements made after
dialysis, on the following midweek interdialysis day, and just
before the next hemodialysis. We were forced to use this
method by the limited availability of portable monitors and the
reluctance of the patients to undergo repeated troublesome
whole-day BP recordings. However, we are confident that our
schedule of monitoring the BP minimized the pitfalls intrinsic to
the variability of scattered BP measurements. Indeed, when we
measured the BP 24 months after the start of the study, there
was good agreement between the BP collected by the arm-cuff
device and that obtained with the portable monitor.
The antihypertensive regimen we used included beta-block-
ers, Ca antagonists and ACE inhibitors. Each of these drugs
might have different and specific effects in lowering the LVM
[19]. However, since it was beyond the scope of this study to
ascertain by which mechanism the cardiac mass of hypertensive
uremic patients was decreased, we gave a combination of these
drugs in order to maximize their co-operative effects in both
lowering the BP and reducing the LVII. The data presented
here demonstrate that prolonged treatment with this type of
combined antihypertensive therapy was able to considerably
decrease the BP of already hypertensive hemodialyzed patients
and to maintain a fairly constant BP level once the BP had
become nearly normal.
In the last few years many factors have been suspected to be
etiopathogenetic factors for LVH in chronic uremic patients,
including uremic toxins, high PTH levels [14, 20] and aluminum
overload [21]. The patients in this study were dialyzed accord-
ing to widely accepted criteria for obtaining adequate dialysis.
Their plasma aluminum levels were normal and did not vary
throughout the study period, nor did their PTH levels.
Experimental studies have demonstrated that arterial pres-
sure overload induces an increase in the end diastolic pressure
which causes the LV to dilate until a concentric thickening of
the wall supervenes, which then renormalizes the already
increased wall stress and brings the left ventricular internal
diameter back to the resting level [22]. In the present study, our
hypertensive patients had dilated left ventricles with increased
septal thickness and nearly normal PW. This picture, which is
the pattern of asymmetrical septal hypertrophy [23], has al-
ready been reported for hemodialyzed uremic patients in pre-
viously published studies [5, 14, 15, 24]. Thus one might
hypothesize that for some unknown reason, the PW of the LV
of the uremic heart is unable to become adequately hypertro-
phic in response to the blood pressure overload, resulting in
isolated septal hypertrophy and a widened internal LV cham-
ber. In dialyzed uremics, however, the extent of LV dilation
might also depend on the relative intravascular volume loading
[25]. In our hypertensive patients, reduction of the blood
pressure caused the EDD to decrease by about 20% and the
IVS by about 13%. Thus, one might think that in these patients
the calculated LVM was mainly decreased through some reduc-
tion of the intravascular volume load that both lowered the BP
and reduced the EDD. To have an indirect estimate of the
intravascular volume loading [7], we measured the interdialytic
weight gains of both groups of patients. Pre-treatment values
for z% body wt of the HDH subjects were similar to those of
the HDN group and did not change thereafter, nor did their
absolute body wt. Therefore, although we neither directly
measured the blood volume nor determined their lean body
mass, we believe it is unlikely that any major changes of the
volume status of our patients might have taken place during the
study period.
The data reported here contrast with previous reports on
larger groups of dialyzed uremics, in whom progressive in-
creases in either the EDD or the IVS were seen in spite of
reported adequate control of the blood pressure [5, 6]. These
reports, however, dealt with studies which were started before
rHuEPO treatment was available.
Our subjects were treated with rHuEPO and care was taken
to keep the Hb levels very close to a concentration of 10 g/dl.
This might explain the differences from the studies above,
which dealt with subjects in whom the underlying anemia might
theoretically have offset the cardiac effects of the antihyperten-
sive therapy. In another study, oral nitrendipine was given to a
group of hemodialyzed hypertensives over a period of 24
weeks, and although it decreased the pre-dialysis BP, it did not
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have measurable effects on heart size [7]. In our study, the
antihypertensive therapy included three drugs and was pro-
longed for two years. Thus, it is possible that differences in
selection criteria, in the mode of assessing the extent of the
blood pressure load, in the antihypertensive drugs used, and in
the length of treatment might all collectively account for the
discrepancies between our findings and those reported by other
groups. Analysis of the individual data revealed that the LVM
of the hypertensive subjects overlapped with those of the
normotensive patients, although their blood pressures did not.
Furthermore, a supranormal average value for LVM in the
HDN group also explained this partial overlap. These observa-
tions might raise the question as to the extent to which the high
blood pressure is really important in inducing LVH in chronic
uremic patients. In the past there has been considerable con-
troversy as to whether the left ventricular hypertrophy of
uremics is specific to them [261. In experimental rats there was
an increase in cardiac mass after subtotal nephrectomy, al-
though the onset of arterial hypertension had been prevented by
antihypertensive drugs and the anemia avoided by blood trans-
fusions [27]. Furthermore, uremic patients are said to have a
particular pathologic form of LVH in which intermyocardio-
cytic fibrosis is much more pronounced than in non-uremic
hypertensive patients [281. Thus we cannot exclude that there
are some factors in patients with chronic uremia unique to the
uremic status which might stimulate some growth of the inter-
stitial ventricular myocardium independently of other causes
known to induce the LVH.
Average values of LVM after 24 months of antihypertensive
therapy were about 34% less than the pre-treatment values.
Furthermore, analysis of the individual data demonstrated that
the LVM of all the patients had decreased, with the final values
for some of them lying below the upper limit of normal levels for
healthy subjects. Thus, this study is the first to demonstrate that
prolonged antihypertensive therapy with strict blood pressure
control can consistently decrease or renormalize the size of the
LV of chronically hemodialyzed uremic patients with LVM
already increased.
Caution, however, must be used in extrapolating the conclu-
sions drawn from our findings to the uremic population at large.
In other poorly selected patients with more severe cardiac
involvement, for example, calcific or isehemic cardiomyopathy,
the likelihood of inducing regression of the LVH with strict
blood pressure control would be poorer than for the small
selected group of patients enrolled in this study.
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